(19)
(11) EP 2 440 200 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.10.2014 Bulletin 2014/42

(45) Mention of the grant of the patent:
27.08.2014 Bulletin 2014/35

(21) Application number: 10786721.0

(22) Date of filing: 08.06.2010
(51) International Patent Classification (IPC): 
A61K 31/195(2006.01)
A61K 31/192(2006.01)
A61P 1/16(2006.01)
 A61K 31/19(2006.01)
A61P 9/12(2006.01)
(86) International application number:
PCT/US2010/037838
(87) International publication number:
WO 2010/144498 (16.12.2010 Gazette 2010/50)

(54)

TREATMENT OF PORTAL HYPERTENSION USING L-ORNITHINE PHENYLACETATE

BEHANDLUNG VON PFORTADERHOCHDRUCK MITTELS L-ORNITHIN-PHENYLACETAT

TRAITEMENT DE L'HYPERTENSION PORTALE AU MOYEN DE PHÉNYLACÉTATE DE L-ORNITHINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 08.06.2009 US 185158 P
19.01.2010 US 296377 P
09.09.2009 US 240748 P

(43) Date of publication of application:
18.04.2012 Bulletin 2012/16

(60) Divisional application:
14175859.9

(73) Proprietors:
  • UCL Business PLC
    London W1T 4TP (GB)
  • Ocera Therapeutics, Inc.
    Palo Alto, CA 94301 (US)

(72) Inventors:
  • JALAN, Rajiv
    Chislehurst BR7 5EP (GB)
  • ANDERSON, Keith
    San Diego CA 92127 (US)

(74) Representative: Bentham, Andrew et al
J A Kemp 14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)


(56) References cited: : 
WO-A1-2006/056794
   
  • WRIGHT G ET AL: "773 REDUCTION IN AMMONIA WITH L-ORNITHINE, PHENYLACETATE (OP) BUT NOT ANTI-TNF PREVENTS LPS INDUCED BRAIN EDEMA IN BILE-DUCT LIGATED CIRRHOTIC RATS", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 50, 1 April 2009 (2009-04-01), page S283, XP026496386, ISSN: 0168-8278, DOI: 10.1016/S0168-8278(09)60775-3 [retrieved on 2009-04-01]
  • JALAN ET AL: "l-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 69, no. 5, 1 January 2007 (2007-01-01), pages 1064-1069, XP022254346, ISSN: 0306-9877, DOI: 10.1016/J.MEHY.2006.12.061
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).